FDA approved drugs:
(show all 8)
# |
|
Drug Name |
Active Ingredient(s) 18
|
Company |
Approval Date |
1 |
|
Afinitor
18
49
|
EVEROLIMUS |
Novartis |
March 2009 |
Disease/s that Drug Treats:renal cell carcinoma/ renal angiomyolipoma associated with tuberous sclerosis complex/ advanced pancreatic neuroendocrine tumors/ hormone receptor-positive, HER2-negative breast cancer
Indications and Usage:
18
AFINITOR is a kinase inhibitor indicated for the treatment of: postmenopausal women with advanced hormone receptor-positive, HER2- negative breast cancer (advanced HR+ BC) in combination with exemestane after failure of treatment with letrozole or anastrozole. (1.1) adults with progressive neuroendocrine tumors of pancreatic origin (PNET) that are unresectable, locally advanced or metastatic. AFINITOR is not indicated for the treatment of patients with functional carcinoid tumors. (1.2) adults with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib. (1.3) adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. The effectiveness of AFINITOR in the treatment of renal angiomyolipoma is based on an analysis of durable objective responses in patients treated for a median of 8.3 months. Further follow-up of patients is required to determine long-term outcomes. (1.4) AFINITOR and AFINITOR DISPERZ are kinase inhibitors indicated for the treatment of: pediatric and adult patients with tuberous sclerosis complex (TSC) who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected. The effectiveness is based on demonstration of durable objective response, as evidenced by reduction in SEGA tumor volume. Improvement in diseaserelated symptoms and overall survival in patients with SEGA and TSC has not been demonstrated. (1.5)
DrugBank Targets:
16
Serine/threonine-protein kinase mTOR
Mechanism of Action:
18
Target: mTOR
Action: inhibitor
FDA: Everolimus is an inhibitor of mammalian target of rapamycin (mTOR), a serine-threonine kinase, downstream of thePI3K/AKT pathway. The mTOR pathway is dysregulated in several human cancers. Everolimus binds to an intracellularprotein, FKBP-12, resulting in an inhibitory complex formation with mTOR complex 1 (mTORC1) and thus inhibition ofmTOR kinase activity. Everolimus reduced the activity of S6 ribosomal protein kinase (S6K1) and eukaryotic initiationfactor 4E-binding protein (4E-BP1), downstream effectors of mTOR, involved in protein synthesis. S6K1 is a substrate ofmTORC1 and phosphorylates the activation domain 1 of the estrogen receptor which results in ligand-independentactivation of the receptor. In addition, everolimus inhibited the expression of hypoxia-inducible factor (e.g., HIF-1) andreduced the expression of vascular endothelial growth factor (VEGF). Inhibition of mTOR by everolimus has been shownto reduce cell proliferation, angiogenesis, and glucose uptake in in vitro and/or in vivo studies.Constitutive activation of the PI3K/Akt/mTOR pathway can contribute to endocrine resistance in breast cancer. In vitrostudies show that estrogen-dependent and HER2+ breast cancer cells are sensitive to the inhibitory effects of everolimus,and that combination treatment with everolimus and Akt, HER2, or aromatase inhibitors enhances the anti-tumor activityof everolimus in a synergistic manner.Two regulators of mTORC1 signaling are the oncogene suppressors tuberin-sclerosis complexes 1 and 2 (TSC1, TSC2).Loss or inactivation of either TSC1 or TSC2 leads to activation of downstream signaling. In TSC, a genetic disorder,inactivating mutations in either the TSC1 or the TSC2 gene lead to hamartoma formation throughout the body.
|
2 |
|
Avastin
18
49
|
BEVACIZUMAB |
Genentech |
July 2009 |
Disease/s that Drug Treats:renal cell carcinoma & Colorectal Cancer
Indications and Usage:
18
Avastin is a vascular endothelial growth factor-specific angiogenesisinhibitor indicated for the treatment of: Metastatic colorectal cancer, with intravenous 5-fluorouracil-basedchemotherapy for first- or second-line treatment. (1.1) Metastatic colorectal cancer, with fluoropyrimidine- irinotecan- orfluoropyrimidine-oxaliplatin-based chemotherapy for second-linetreatment in patients who have progressed on a first-line Avastincontainingregimen. (1.1) Non-squamous non-small cell lung cancer, with carboplatin and paclitaxelfor first line treatment of unresectable, locally advanced, recurrent ormetastatic disease. (1.2) Glioblastoma, as a single agent for adult patients with progressive diseasefollowing prior therapy. (1.3)-Effectiveness based on improvement in objective response rate. No dataavailable demonstrating improvement in disease-related symptoms orsurvival with Avastin. Metastatic renal cell carcinoma with interferon alfa (1.4) Cervical cancer, in combination with paclitaxel and cisplatin or paclitaxeland topotecan in persistent, recurrent, or metastatic disease. (1.5) Platinum-resistant recurrent epithelial ovarian, fallopian tube or primaryperitoneal cancer, in combination with paclitaxel, pegylated liposomaldoxorubicin or topotecan (1.6) Limitation of Use: Avastin is not indicated for adjuvant treatment of coloncancer. (1.1)
DrugBank Targets:
16
1. Vascular endothelial growth factor A;2. Low affinity immunoglobulin gamma Fc region receptor III-B;3. Complement C1r subcomponent;4. Complement C1q subcomponent subunit A;5. Complement C1q subcomponent subunit B;6. Complement C1q subcomponent subunit C;7. Low affinity immunoglobulin gamma Fc region receptor III-A;8. High affinity immunoglobulin gamma Fc receptor I;9. Low affinity immunoglobulin gamma Fc region receptor II-a;10. Low affinity immunoglobulin gamma Fc region receptor II-b;11. Low affinity immunoglobulin gamma Fc region receptor II-c
Mechanism of Action:
18
Target: VEGF
Action: inhibitor
FDA: Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR)697 on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial698 cell proliferation and new blood vessel formation in in vitro models of angiogenesis. Administration699 of bevacizumab to xenotransplant models of colon cancer in nude (athymic) mice caused reduction700 of microvascular growth and inhibition of metastatic disease progression
|
3 |
|
Doxil
18
49
|
DOXORUBICIN HYDROCHLORIDE |
Alza |
June 1999 |
Disease/s that Drug Treats:ovarian cancer that is refractory to other first-line therapies
Indications and Usage:
18
DOXIL is an anthracycline topoisomerase II inhibitor indicated for: Ovarian cancer (1.1)After failure of platinum-based chemotherapy. AIDS-related Kaposi’s Sarcoma (1.2)After failure of prior systemic chemotherapy or intolerance to such therapy. Multiple Myeloma (1.3)In combination with bortezomib in patients who have not previouslyreceived bortezomib and have received at least one prior therapy.
DrugBank Targets:
16
1. DNA;2. DNA topoisomerase 2-alpha
Mechanism of Action:
18
Target: nucleic acidsynthesis
Action: inhibitor
FDA: The active ingredient of DOXIL is doxorubicin HCl. The mechanism of action ofdoxorubicin HCl is thought to be related to its ability to bind DNA and inhibit nucleic acidsynthesis. Cell structure studies have demonstrated rapid cell penetration and perinuclearReference ID: 373359617 chromatin binding, rapid inhibition of mitotic activity and nucleic acid synthesis, andinduction of mutagenesis and chromosomal aberrations.
|
4 |
|
Marqibo
18
49
|
VINCRISTINE SULFATE |
Talon Therapeutics |
August 2012 |
Disease/s that Drug Treats:Ph- acute lymphoblastic leukemia
Indications and Usage:
18
Marqibo is a vinca alkaloid indicated for the treatment of adult patients withPhiladelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL)in second or greater relapse or whose disease has progressed following two ormore anti-leukemia therapies. This indication is based on overall responserate. Clinical benefit such as improvement in overall survival has not beenverified (1.1).
DrugBank Targets:
16
1. Tubulin beta chain;2. Tubulin alpha-4A chain
Mechanism of Action:
18
Target: tubulin
Action: alters polymerization equilibrium
FDA: Marqibo is a sphingomyelin/cholesterol liposome-encapsulated formulation of vincristine sulfate.Non-liposomal vincristine sulfate binds to tubulin, altering the tubulin polymerization equilibrium, resulting inaltered microtubule structure and function. Non-liposomal vincristine sulfate stabilizes the spindle apparatus,preventing chromosome segregation, triggering metaphase arrest and inhibition of mitosis.
|
5 |
|
DuoNeb
18
|
ALBUTEROL SULFATE; IPRATROPIUM BROMIDE |
Dey Laboratories |
March 2001 |
Disease/s that Drug Treats:Bronchospasm associated with COPD for patients who require more than one bronchodilator
Indications and Usage:
18
DuoNeb® - (Ipratropium Bromide 0.5 mg/Albuterol Sulfate 3.0 mg*) - Inhalation Solution - *Equivalent to 2.5 mg albuterol base - DESCRIPTION - The active components in DuoNeb® Inhalation Solution are albuterol sulfate and ipratropium bromide. Albuterol sulfate, is a salt of racemic albuterol and a relatively selective β2-adrenergic bronchodilator chemically described as α1-[(tert-butylamino)methyl]-4-hydroxy-mxylene-α, α'-diol sulfate (2:1) (salt). It has a molecular weight of 576.7 and the empirical formula is (C13H21NO3)2*H2SO4. It is a white crystalline powder, soluble in water and slightly soluble in ethanol. The World Health Organization recommended name for albuterol base is salbutamol.Ipratropium bromide is an anticholinergic bronchodilator chemically described as 8- azoniabicyclo [3.2.1]-octane, 3-(3-hydroxy-1-oxo-2-phenylpropoxy)-8methyl-8-(1- methylethyl)-, bromide, monohydrate (endo, syn)-, (±)-; a synthetic quaternary ammonium compound, chemically related to atropine. It has a molecular weight of 430.4 and the empirical formula is C20H30BrNO3*H2O. It is a white crystalline substance, freely soluble in water and lower alcohols, and insoluble in lipophilic solvents such as ether, chloroform, and fluorocarbons.
DrugBank Targets:
16
16
Muscarinic acetylcholine receptor M1|Muscarinic acetylcholine receptor M2|Muscarinic acetylcholine receptor M3|Beta-2 adrenergic receptor|Beta-1 adrenergic receptor
Mechanism of Action:
18
Target: beta2-adrenergic|acetylcholine
Action: bronchodilator|blocker of physiologic action
FDA: -
|
6 |
|
Rayos
18
|
PREDNISONE |
Horizon Pharma |
July of 2012 |
Disease/s that Drug Treats:certain inflammatory diseases, including arthritis, COPD, asthma and psoriatic conditions
Indications and Usage:
18
RAYOS is a corticosteroid indicated * as an anti-inflammatory or immunosuppressive agent for certain allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, specific infectious diseases or conditions and organ transplantation (1) * for the treatment of certain endocrine conditions (1) * for palliation of certain neoplastic conditions (1)
DrugBank Targets:
16
Glucocorticoid receptor|Corticosteroid 11-beta-dehydrogenase isozyme 1
Mechanism of Action:
18
Target: many organ systems
Action: anti-inflammatory
FDA: Naturally occurring corticosteroids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs, such as prednisone, are primarily used for their potent antiinflammatory effects in disorders of many organ systems. Corticosteroids, such as prednisone, cause profound and varied metabolic effects. In addition, they modify the body’s immune responses to diverse stimuli. Prednisone is a synthetic adrenocortical steroid drug with predominantly corticosteroid properties. Some of these properties reproduce the physiological actions of endogenous glucocorticosteroids, but others do not necessarily reflect any of the adrenal hormones’ normal functions; they are seen only after administration of large therapeutic doses of the drug. The pharmacological effects of prednisone which are due to its corticosteroid properties include: promotion of gluconeogenesis; increased deposition of glycogen in the liver; inhibition of the utilization of glucose; anti-insulin activity; increased catabolism of protein; increased lipolysis; stimulation of fat synthesis and storage; increased glomerular filtration rate and resulting increase in urinary excretion of urate (creatinine excretion remains unchanged); and increased calcium excretion. Depressed production of eosinophils and lymphocytes occurs, but erythropoiesis and production of polymorphonuclear leukocytes are stimulated. Inflammatory processes (edema, fibrin deposition, capillary dilatation, migration of leukocytes and phagocytosis) and the later stages of wound healing (capillary proliferation, deposition of collagen, cicatrization) are inhibited. Prednisone can stimulate secretion of various components of gastric juice. Suppression of the production of corticotropin may lead to suppression of endogenous corticosteroids. Prednisone has slight mineralocorticoid activity, whereby entry of sodium into cells and loss of intracellular potassium is stimulated. This is particularly evident in the kidney, where rapid ion exchange leads to sodium retention and hypertension.
|
7 |
|
Vibativ
18
|
* TELAVANCIN * TELAVANCIN HYDROCHLORIDE |
Theravance |
June 2013 |
Disease/s that Drug Treats:hospital-acquired and ventilator-associated bacterial pneumonia caused by staph aureus
Indications and Usage:
18
VIBATIV is a lipoglycopeptide antibacterial drug indicated for the treatment of the following infections in adult patients caused by designated susceptible bacteria: * Complicated skin and skin structure infections (cSSSI) (1.1) * Hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Staphylococcus aureus. VIBATIV should be reserved for use when alternative treatments are not suitable. (1.2)
DrugBank Targets:
-
Mechanism of Action:
18
Target: late-stage peptidoglycan precursors
Action: inhibits cell wall biosynthesis
FDA: Telavancin is an antibacterial drug [see Clinical Pharmacology (12.4)]. Telavancin inhibits cell wall biosynthesis by binding to late-stage peptidoglycan precursors, including lipid II. Telavancin also binds to the bacterial membrane and disrupts membrane barrier function.
|
8 |
|
Zyflo
18
|
ZILEUTON |
Abbott Laboratories |
January 1997 |
Disease/s that Drug Treats:asthma
Indications and Usage:
18
ZYFLO is indicated for the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older.
DrugBank Targets:
16
Arachidonate 5-lipoxygenase
Mechanism of Action:
18
Target: 5-lipoxygenase (5-LO)
Action: inhibitor
FDA: Zileuton is a specific inhibitor of 5-lipoxygenase and thus inhibits leukotriene (LTB4, LTC4, LTD4, and LTE4) formation. Both the R(+) and S(-) enantiomers are pharmacologically active as 5-lipoxygenase inhibitors in in vitro systems. Leukotrienes are substances that induce numerous biological effects including augmentation of neutrophil and eosinophil migration, neutrophil and monocyte aggregation, leukocyte adhesion, increased capillary permeability, and smooth muscle contraction. These effects contribute to inflammation, edema, mucus secretion, and bronchoconstriction in the airways of asthmatic patients. Sulfido-peptide leukotrienes (LTC4, LTD4, LTE4, also known as the slow-releasing substances of anaphylaxis) and LTB4, a chemoattractant for neutrophils and eosinophils, can be measured in a number of biological fluids including bronchoalveolar lavage fluid (BALF) from asthmatic patients. Zileuton is an orally active inhibitor of ex vivo LTB4 formation in several species, including dogs, monkeys, rats, sheep, and rabbits. Zileuton inhibits arachidonic acidinduced ear edema in mice, neutrophil migration in mice in response to polyacrylamide gel, and eosinophil migration into the lungs of antigen-challenged sheep. Zileuton inhibits leukotriene-dependent smooth muscle contractions in vitro in guinea pig and human airways. The compound inhibits leukotriene-dependent bronchospasm in antigen and arachidonic acid-challenged guinea pigs. In antigen-challenged sheep, zileuton inhibits late-phase bronchoconstriction and airway hyperreactivity. In humans, pretreatment with zileuton attenuated bronchoconstriction caused by cold air challenge in patients with asthma.
|
Drugs for Lipomatosis, Multiple (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 36)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Prednisolone phosphate |
Approved, Vet_approved |
Phase 1, Phase 2 |
|
302-25-0 |
|
Synonyms:
Prednisolone 21-(dihydrogen phosphate)
Prednisolone 21-monophosphate
|
Prednisolone 21-phosphate
|
|
2 |
|
Methylprednisolone |
Approved, Vet_approved |
Phase 1, Phase 2 |
|
83-43-2 |
6741
|
Synonyms:
(6a,11b)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
(6α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione
.DELTA.1-6.alpha.-Methylhydrocortisone
11beta,17,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
11-beta,17,21-Trihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methyl-1,4-pregnadiene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
121673-01-6
1-dehydro-6alpha-Methylhydrocortisone
1-Dehydro-6alpha-methylhydrocortisone
1-dehydro-6a-Methylhydrocortisone
1-dehydro-6α-methylhydrocortisone
4-08-00-03498 (Beilstein Handbook Reference)
46436_FLUKA
46436_RIEDEL
570-35-4
6 Methylprednisolone
6.alpha.-Methylprednisolone
6923-42-8
6alpha-Methyl-11beta,17alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione
6alpha-methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
6alpha-Methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
6alpha-Methylprednisolone
6-alpha-Methylprednisolone
6a-Methyl-11b,17a,21-triol-1,4-pregnadiene-3,20-dione
6-Methylprednisolone
6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
83-43-2
AC1L1N7A
Artisone-wyeth
Artisone-Wyeth
Besonia
Bio-0658
BPBio1_000174
BRD-K35240538-001-03-1
BRN 2340300
BSPBio_000158
CHEBI:6888
CHEMBL650
CID6741
CPD000058330
D00407
D008775
DB00959
delta(1)-6alpha-Methylhydrocortisone
Delta(1)-6alpha-Methylhydrocortisone
delta(1)-6a-Methylhydrocortisone
delta(sup 1)-6-alpha-Methylhydrocortisone
Depo-Medrol (acetate)
Dopomedrol
EINECS 201-476-4
Esametone
Firmacort
HMS1568H20
HMS2090B13
HSDB 3127
Lemod
LMST02030178
LS-118498
M0639_SIGMA
M1665
Medesone
Medixon
Medlone 21
Medrate
Medric acid
|
Medrol
Medrol (TN)
Medrol adt pak
Medrol Adt Pak
Medrol dosepak
Medrol Dosepak
Medrol, Solu-Medrol, Medrone, Methylprednisolone
Medrone
MEPRDL
Mesopren
Metastab
Methyleneprednisolone
Methylprednisolon
methylprednisolone
Methylprednisolone
Methylprednisolone (JP15/USP/INN)
Methylprednisolone [USAN:INN:BAN:JAN]
Methylprednisolone, 6-alpha
Methylprednisolonum
Methylprednisolonum [INN-Latin]
methylprenisolone
Metilbetasone
Metilprednisolona
Metilprednisolona [INN-Spanish]
Metilprednisolone
Metilprednisolone [Dcit]
Metilprednisolone [DCIT]
Metipred
Metrisone
Metrocort
Metysolon
MLS000028541
MLS001148159
MLS002207191
Moderin
MolPort-002-528-554
NCGC00022735-03
NCI60_001657
Nirypan
Noretona
NSC19987
NSC-19987
Predni N Tablinen
Prednol- L
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-6alpha-methyl- (8CI)
Prestwick_622
Prestwick0_000279
Prestwick1_000279
Prestwick2_000279
Prestwick3_000279
Promacortine
Reactenol
S1733_Selleck
SAM002589984
Sieropresol
SMR000058330
Solomet
SPBio_002377
Summicort
Suprametil
U 7532
UNII-X4W7ZR7023
Urbason
Urbasone
Wyacort
ZINC03875560
δ(1)-6a-methylhydrocortisone
δ(1)-6α-methylhydrocortisone
|
|
3 |
|
Prednisolone |
Approved, Vet_approved |
Phase 1, Phase 2 |
|
50-24-8 |
5755
|
Synonyms:
(11b)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
(11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
(11β)-11,17,21-trihydroxypregna-1,4-diene-3,20-dione
.DELTA.1-Cortisol
.DELTA.1-Dehydrocortisol
.DELTA.1-Dehydrohydrocortisone
.DELTA.1-Hydrocortisone
.delta.-Cortef
.delta.-Stab
1,2-Dehydrohydrocortisone
1,4-Pregnadiene-11b,17a,21-triol-3,20-dione
1,4-Pregnadiene-11beta,17alpha,21-triol-3,20-dione
1,4-pregnadiene-11β,17α,21-triol-3,20-dione
1,4-Pregnadiene-11β,17α,21-triol-3,20-dione
1,4-Pregnadiene-3,20-dione-11b,17a,21-triol
1,4-Pregnadiene-3,20-dione-11beta,17alpha,21-triol
1,4-pregnadiene-3,20-dione-11β,17α,21-triol
1,4-Pregnadiene-3,20-dione-11β,17α,21-triol
1-Dehydrocortisol
1-Dehydrohydrocortisone
3,20-dioxo-11b,17a,21-Trihydroxy-1,4-pregnadiene
3,20-dioxo-11beta,17alpha,21-Trihydroxy-1,4-pregnadiene
3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
46656_FLUKA
46656_RIEDEL
50-24-8
58201-11-9
8056-11-9
AC-1773
AC1L1L2E
Ak-Pred
Ak-Tate
Alphadrol
Articulose-50
Bio-0666
BPBio1_000164
BRD-K98039984-001-03-0
BRN 1354103
BSPBio_000148
Bubbli-Pred
C07369
CCRIS 980
CHEBI:8378
CHEMBL131
CID5755
Codelcortone
Co-Hydeltra
CO-Hydeltra
component of Ataraxoid
component of K-Predne-Dome
Cordrol
Cortalone
Cotogesic
Cotolone
CPD000718761
D00472
D011239
DB00860
Decaprednil
Decortin H
Delcortol
Delta F
delta(1)-Cortisol
delta(1)-Dehydrocortisol
Delta(1)-Dehydrocortisol
delta(1)-Dehydrohydrocortisone
Delta(1)-dehydrohydrocortisone
Delta(1)-Dehydrohydrocortisone
delta(1)-Hydrocortisone
Delta(1)-Hydrocortisone
delta(sup 1)-Cortisol
delta(sup 1)-Dehydrocortisol
delta(sup 1)-Dehydrohydrocortisone
delta(sup 1)-Hydrocortisone
Delta-Cortef
Delta-Cortef (TN)
Deltacortenol
Deltacortril
Deltacortril Enteric
delta-dehydrocortisol
delta-dehydrohydrocortisone
Delta-Ef-Cortelan
delta-hydrocortisone
Deltahydrocortisone
Deltasolone
Delta-stab
Delta-Stab
Deltisilone
Depo-Medrol
Derpo Pd
Derpo PD
Dexa-Cortidelt hostacortin H
Dexa-Cortidelt Hostacortin H
Di adreson F
Di Adreson F
Di-adreson F
Di-Adreson F
Di-adreson-F
DiAdresonF
Di-Adreson-F
Dicortol
Donisolone
Dydeltrone
Eazolin D
Econopred
Econopred Plus
EINECS 200-021-7
Erbacort
Erbasona
Estilsona
Fernisolone
Fernisolone P
Fernisolone-P
Flamasone
HMS1568H10
HMS2090J05
Hostacortin H
HSDB 3385
Hydeltra
Hydeltrasol
Hydeltra-Tba
|
Hydeltrone
Hydrodeltalone
Hydrodeltisone
Hydroretrocortin
Hydroretrocortine
Inflamase Forte
Inflamase Mild
I-Pred
K 1557
Key-Pred
Klismacort
Lentosone
Lite Pred
LMST02030179
LS-7669
Medrol
Medrol Acetate
Metacortandralone
Methylprednisolone acetate
Methylprednisolone Acetate
Meticortelone
Meti-Derm
Metreton
MLS001304083
MLS002154250
MLS002207037
MolPort-002-507-147
M-Predrol
NCGC00179649-01
Neo-Delta-Cortef
Nisolone
Nor-Pred T.B.A.
NSC 9120
NSC9120
NSC9900
Ocu-Pred
Ocu-Pred Forte
Ophtho-Tate
Orapred
P0152_SIGMA
P0637
P6004_SIGMA
Panafcortelone
Paracortol
Paracotol
Pediapred
Poly-Pred
PRDL
Precortalon
Precortancyl
Precortilon
Precortisyl
Pred Forte
Pred Mild
Predair
Predair A
Predair Forte
Predalone 50
Predalone T.B.A.
Predate
Predate Tba
Predate-50
Predcor-25
Predcor-50
Predcor-Tba
PRED-G
Predisolone sodium phosphate
Predisolone Sodium Phosphate
Predne-Dome
Prednelan
Prednicen
Predni-Dome
Predniliderm
Predniretard
Prednis
Prednisolona
Prednisolona [INN-Spanish]
prednisolone
Prednisolone (anhydrous)
Prednisolone (JP15/USP/INN)
Prednisolone [INN:BAN:JAN]
Prednisolone acetate
Prednisolone Acetate
Prednisolone sodium phosphate
Prednisolone Sodium Phosphate
Prednisolone tebutate
Prednisolone Tebutate
Prednisolonum
Prednisolonum [INN-Latin]
Predonin
Predonine
Prelone
Prenolone
Prestwick_404
Prestwick0_000274
Prestwick1_000274
Prestwick2_000274
Prestwick3_000274
Rolisone
S1737_Selleck
SAM002264639
Scherisolon
SMR000718761
Solone
SPBio_002367
Steran
Sterane
Sterolone
Supercortisol
Ulacort
Ultra Pred
Ultracorten H
Ultracortene H
Ultracortene-H
Ultracortene-hydrogen
Ultracortene-Hydrogen
UNII-9PHQ9Y1OLM
ZINC03833821
δ(1)-dehydrocortisol
δ(1)-dehydrohydrocortisone
δ(1)-hydrocortisone
|
|
4 |
|
Methylprednisolone hemisuccinate |
Approved |
Phase 1, Phase 2 |
|
2921-57-5 |
|
Synonyms:
Methylprednisolone hydrogen succinate
|
Methylprednisolone succinate
|
|
5 |
|
Cortisone acetate |
Approved, Investigational |
Phase 1, Phase 2 |
|
1950-04-4, 50-04-4 |
5745
|
Synonyms:
Adreson
Cortisone
Cortisone acetic acid
|
Cortisyl
Cortone acetate
Cortone acetic acid
|
|
6 |
|
Isoproterenol |
Approved, Investigational |
Phase 1, Phase 2 |
|
7683-59-2 |
3779
|
Synonyms:
(-)-Isoproterenol hydrochloride
(+)-Isoprenaline
(+-)-Isoprenaline
(+)-Isoproterenol
(+-)-Isoproterenol
(±)-isoprenaline
(±)-isoproterenol
(S)-(+)-Isoproterenol
(S)-Isoprenaline
(S)-Isoproterenol
.alpha.-(Isopropylaminomoethyl)protocatechuyl alcohol
1-(3,4-Dihydroxyphenyl)-2-(isopropylamino)ethanol
1-(3,4-Dihydroxyphenyl)-2-isopropylaminoethanol
1,2-Benzenediol, 4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)- (9CI)
1,2-Benzenediol, 4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)-, (S)- (9CI)
149-53-1
2964-04-7
3,4-Dihydroxy-.alpha.-(isopropylaminomethyl)-benzyl alcohol
3,4-Dihydroxy-.alpha.-[(isopropylamino)methyl]benzyl alcohol
3,4-Dihydroxy-a-[(isopropylamino)methyl]benzyl alcohol
3,4-Dihydroxy-alpha-((isopropylamino)methyl)benzyl alcohol
3,4-Dihydroxy-alpha-[(isopropylamino)methyl]benzyl alcohol
3,4-Dihydroxy-α-[(isopropylamino)methyl]benzyl alcohol
3-13-00-02387 (Beilstein Handbook Reference)
4-(1-Hydroxy-2-((1-methylethyl)amino)ethyl)-1,2-benzenediol
4-(1-Hydroxy-2(isopropylamino)ethyl)-benzene 1,2-diol
4-{1-hydroxy-2-[(1-methylethyl)amino]ethyl}benzene-1,2-diol
46388-38-9
7683-59-2
a-(Isopropylaminomethyl)protocatechuyl alcohol
AC1L1GOZ
AC1Q1QBS
Aerolone
Aleudrin
Aleudrine
alpha-(Isopropylaminomethyl)protocatechuyl alcohol
Aludrin
Aludrine
Asiprenol
Asmalar
Assiprenol
Bellasthman
BRN 2213857
Bronkephrine
BSPBio_002208
C07056
CCRIS 3081
CHEMBL434
CID3779
D08090
DB01064
Dihydroxyphenylethanolisopropylamine
d-Isoprenaline
d-Isopropylarterenol
d-Isoproterenol
DivK1c_000894
DL(+-)-Isoproterenol
dl-Ipr
dl-Isadrine
dl-Isopropylnoradrenaline
DL-Isopropylnorepinephrine
dl-N-Isopropylnoradrenaline
d-N-Isopropylnorepinephrine
EINECS 231-687-7
Epinephrine isopropyl homolog
Epinephrine Isopropyl Homolog
Euspiran
HMS2089A12
Hydrochloride, isoproterenol
ICI 46399
IDI1_000894
IPA
Isadrin
Isadrine
Isonorene
Isonorin
Isoprenalin
Isoprenalina
Isoprenalina [INN-Spanish]
Isoprenaline
Isoprenaline (INN)
Isoprenaline hydrochloride
Isoprenalinum
Isoprenalinum [INN-Latin]
ISOPROP
Isopropydrin
Isopropyl noradrenaline
Isopropyladrenaline
Isopropylaminomethyl(3,4-dihydroxyphenyl)carbinol
Isopropylaminomethyl-3,4-dihydroxyphenyl carbinol
|
Isopropylarterenol
Isopropylnoradrenaline
Isopropylnorepinephrine
isoproterenol
Isoproterenol
Isoproterenol [JAN]
Isoproterenol chloride
Isoproterenol Chloride
Isoproterenol HCl
Isoproterenol hydrochloride
Isoproterenol sulfate
Isoproterenolum
Isorenin
Isuprel
Isuprel Mistometer
Isupren
Izadrin
KBio1_000894
KBio2_001429
KBio2_003997
KBio2_006565
KBio3_001428
KBioGR_000427
KBioSS_001429
L000936
l-Isopropylnoradrenaline
L-Isopropylnoradrenaline
l-Isoproterenol
L-Isoproterenol
Lomupren
Lopac0_000711
LS-42866
LS-42868
LS-42869
Medihaler-Iso
Medihaler-ISO
MolPort-001-783-449
NCGC00015558-08
NCGC00025274-03
NCGC00025274-04
NCGC00162220-01
nchembio.307-comp1
nchembio801-comp2
nchembio882-comp6
Neodrenal
neo-Epinine
Neo-Epinine
NINDS_000894
N-Isopropyl-b-dihydroxyphenyl-b-hydroxyethylamine
N-Isopropyl-beta-dihydroxyphenyl-beta-hydroxyethylamine
N-Isopropylnoradrenaline
N-Isopropylnorepinephrine
N-isopropyl-β-dihydroxyphenyl-β-hydroxyethylamine
N-Isopropyl-β-dihydroxyphenyl-β-hydroxyethylamine
Noradrenaline, isopropyl
Norisodrine
Norisodrine Aerotrol
Novodrin
NSC 33791
NSC 9975
NSC33791
NSC9975
Oprea1_009434
PDSP1_001425
PDSP2_001409
Prestwick0_001097
Prestwick1_001097
Prestwick2_001097
Proternol
Racemic isoprenaline
Racemic isoproterenol
Respifral
Saventrine
SGCUT00015
SPBio_001042
SPBio_003057
Spectrum_000949
Spectrum2_001061
Spectrum3_000474
Spectrum4_000024
Spectrum5_000880
STOCK1N-00740
Sulfate, isoproterenol
to_000062
UNII-L628TT009W
Vapo-Iso
Vapo-N-iso
WIN 5162
WLN: QR BQ DYQ1MY1&1
α-(isopropylaminomethyl)protocatechuyl alcohol
|
|
7 |
|
deoxycholic acid |
Approved |
Phase 2,Phase 1 |
|
83-44-3 |
222528
|
Synonyms:
(3a,5a,12a)-3,12-DIHYDROXYCHOLAN-24-Oate
(3a,5a,12a)-3,12-DIHYDROXYCHOLAN-24-Oic acid
(3a,5b,12a)-3,12-Dihydroxycholan-24-Oate
(3a,5b,12a)-3,12-Dihydroxycholan-24-Oic acid
(3alpha,5alpha,12alpha)-3,12-DIHYDROXYCHOLAN-24-Oate
(3ALPHA,5ALPHA,12ALPHA)-3,12-DIHYDROXYCHOLAN-24-OIC ACID
(3alpha,5beta,12alpha)-3,12-Dihydroxycholan-24-Oate
(3alpha,5beta,12alpha)-3,12-Dihydroxycholan-24-Oic acid
(3α,5α,12α)-3,12-dihydroxycholan-24-Oate
(3α,5α,12α)-3,12-dihydroxycholan-24-Oic acid
(3α,5β,12α)-3,12-dihydroxycholan-24-Oate
(3α,5β,12α)-3,12-dihydroxycholan-24-oic acid
(3α,5β,12α)-3,12-dihydroxycholan-24-Oic acid
12beta-Isomer deoxycholic acid
3a,12a-Dihydroxy-5b-cholanate
3a,12a-Dihydroxy-5b-cholanic acid
3alpha,12alpha-Dihydroxy-5beta-cholanate
3alpha,12alpha-Dihydroxy-5beta-cholanic acid
3beta-Isomer deoxycholic acid
3α,12α-dihydroxy-5β-cholanate
3α,12α-dihydroxy-5β-cholanic acid
5alpha-Isomer deoxycholic acid
5b-Cholanic acid-3a,12a-diol
5b-Deoxycholate
5b-Deoxycholic acid
7a-Deoxycholate
7a-Deoxycholic acid
7alpha-Deoxycholate
7alpha-Deoxycholic acid
7-Deoxycholate
7-Deoxycholic acid
7α-deoxycholate
7α-deoxycholic acid
Acid, 5alpha-isomer deoxycholic
Acid, choleic
|
Acid, deoxycholic
Acid, desoxycholic
Acid, dihydroxycholanoic
Acid, lagodeoxycholic
Choleic acid
Cholerebic
Cholorebic
Degalol
Deoxycholatate
deoxycholate
Deoxycholate
Deoxy-cholate
Deoxycholate, sodium
Deoxycholatic acid
Deoxy-cholic acid
Deoxycholic acid, 12beta isomer
Deoxycholic acid, 12beta-isomer
Deoxycholic acid, 3beta isomer
Deoxycholic acid, 3beta-isomer
Deoxycholic acid, 5alpha isomer
Deoxycholic acid, 5alpha-isomer
Deoxycholic acid, disodium salt
Deoxycholic acid, magnesium (2:1) salt
Deoxycholic acid, monoammonium salt
Deoxycholic acid, monopotassium salt
Deoxycholic acid, monosodium salt
Deoxycholic acid, sodium salt, 12beta-isomer
Desoxycholate
desoxycholic acid
Desoxycholic acid
Desoxycholsaeure
Desoxycholsäure
Dihydroxycholanoic acid
Lagodeoxycholic acid
Sodium deoxycholate
|
|
8 |
|
Prednisolone hemisuccinate |
Experimental |
Phase 1, Phase 2 |
|
2920-86-7 |
|
Synonyms:
(+)-prednisolone hemisuccinate
Prednisolonbisuccinat
Prednisolone 21-hemisuccinate
Prednisolone 21-succinate
|
Prednisolone bisuccinate
Prednisolone hydrogen succinate
Prednisolone succinate
|
|
9 |
|
Cortisone |
Experimental |
Phase 1, Phase 2 |
|
53-06-5 |
222786
|
Synonyms:
11-dehydro-17-hydroxycorticosterone
11-dehydro-17-Hydroxycorticosterone
17a,21-Dihydroxy-4-pregnene-3,11,20-trione
17alpha,21-Dihydroxy-4-pregnene-3,11,20-trione
17-Hydroxy-11-dehydrocorticosterone
17α,21-dihydroxy-4-pregnene-3,11,20-trione
4-Pregnene-17a,21-diol-3,11,20-trione
4-Pregnene-17alpha,21-diol-3,11,20-trione
4-pregnene-17α,21-diol-3,11,20-trione
4-Pregnene-17α,21-diol-3,11,20-trione
Adreson
Andreson
Anusol HC
Balneol-HC
beta-HC
Colocort
Compound e
Corlin
Cortadren
Cortandren
Cortef
Cortef acetate
Cortisal
Cortisate
Cortison
Cortisona
Cortisone acetate
Cortisonum
Cortistal
Cortivite
Cortogen
Cortone
Cortril
delta(4)-Pregnene-17a,21-diol-3,11,20-trione
Delta(4)-Pregnene-17alpha,21-diol-3,11,20-trione
|
Dermacort
Dricort
Flexicort
Florinef
Fludrocortisone acetate
Glycort
Hemsol-HC
Hi-cor
Incortin
Kendall'S compound
Kendall's compound e
Kendall's compound E
Kortison
Locoid
Locoid lipocream
Micort-HC
Nogenic HC
Orabase hca
Pandel
Pregn-4-en-17a,21-diol-3,11,20-trione
Pregn-4-en-17alpha,21-diol-3,11,20-trione
pregn-4-en-17α,21-diol-3,11,20-trione
Pregn-4-en-17α,21-diol-3,11,20-trione
Prestwick_132
Reichstein fa
Reichstein's substance fa
Reichstein's substance Fa
Scheroson
Solu-cortef
Stie-cort
Texacort
Westcort
Wintersteiner's compound F
δ(4)-pregnene-17a,21-diol-3,11,20-trione
δ(4)-pregnene-17α,21-diol-3,11,20-trione
|
|
10 |
|
Pharmaceutical Solutions |
|
Phase 1, Phase 2,Not Applicable |
|
|
|
11 |
|
Sympathomimetics |
|
Phase 1, Phase 2 |
|
|
|
12 |
|
Respiratory System Agents |
|
Phase 1, Phase 2 |
|
|
|
13 |
|
Adrenergic beta-Agonists |
|
Phase 1, Phase 2 |
|
|
|
14 |
|
Antineoplastic Agents, Hormonal |
|
Phase 1, Phase 2 |
|
|
|
15 |
|
Hormones, Hormone Substitutes, and Hormone Antagonists |
|
Phase 1, Phase 2 |
|
|
|
16 |
|
Hormones |
|
Phase 1, Phase 2 |
|
|
|
17 |
|
Adrenergic Agonists |
|
Phase 1, Phase 2 |
|
|
|
18 |
|
Anti-Inflammatory Agents |
|
Phase 1, Phase 2 |
|
|
|
19 |
|
Hormone Antagonists |
|
Phase 1, Phase 2 |
|
|
|
20 |
|
Prednisolone acetate |
|
Phase 1, Phase 2 |
|
|
|
21 |
|
Peripheral Nervous System Agents |
|
Phase 1, Phase 2 |
|
|
|
22 |
|
Bronchodilator Agents |
|
Phase 1, Phase 2 |
|
|
|
23 |
|
Gastrointestinal Agents |
|
Phase 1, Phase 2,Phase 2 |
|
|
|
24 |
|
Neuroprotective Agents |
|
Phase 1, Phase 2 |
|
|
|
25 |
|
Autonomic Agents |
|
Phase 1, Phase 2 |
|
|
|
26 |
|
Anti-Asthmatic Agents |
|
Phase 1, Phase 2 |
|
|
|
27 |
|
Antiemetics |
|
Phase 1, Phase 2 |
|
|
|
28 |
|
glucocorticoids |
|
Phase 1, Phase 2 |
|
|
|
29 |
|
Neurotransmitter Agents |
|
Phase 1, Phase 2 |
|
|
|
30 |
|
Adrenergic Agents |
|
Phase 1, Phase 2 |
|
|
|
31 |
|
Protective Agents |
|
Phase 1, Phase 2 |
|
|
|
32 |
|
Cardiotonic Agents |
|
Phase 1, Phase 2 |
|
|
|
33 |
|
Methylprednisolone acetate |
|
Phase 1, Phase 2 |
|
|
|
34 |
|
Cholagogues and Choleretics |
|
Phase 2,Phase 1 |
|
|
|
35 |
|
Endothelial Growth Factors |
|
|
|
|
|
36 |
|
Mitogens |
|
|
|
|
|
Interventional clinical trials:
(show all 15)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
A Dose Escalation Study Using Collagenase Clostridium Histolyticum in the Treatment of Lipoma |
Completed |
NCT01613313
|
Phase 2 |
Collagenase Clostridium Histolyticum |
2 |
Double Blind Study to Evaluate the Efficacy of Collagenase Histolyticum in the Treatment of Lipoma |
Completed |
NCT02249052
|
Phase 2 |
AA4500;placebo |
3 |
Association of Beta-2 Adrenergic Agonist and Corticosteroid Injection in the Treatment of Lipomas |
Completed |
NCT00624416
|
Phase 1, Phase 2 |
Prednisolone synthetic cortisone and Isoproterenol together |
4 |
Phase 2 Study for the Treatment of Superficial Lipomas |
Completed |
NCT00608842
|
Phase 2 |
Deoxycholic Acid Injection;Placebo |
5 |
Evaluation of Safety and Efficacy of RZL-012 for the Treatment of Lipedema or of Nodular Dercum's Disease |
Recruiting |
NCT03492840
|
Phase 2 |
RZL-012 |
6 |
Deoxycholic Acid Injection for the Treatment of Superficial Lipomas |
Completed |
NCT00422188
|
Phase 1 |
Deoxycholic Acid Injection;Placebo |
7 |
Developing a Biomarker for Monitoring Clinical Outcomes in Children With Spinal Lipoma. |
Unknown status |
NCT02722681
|
|
|
8 |
Survey of Optical Values of the Breast Using Radiation-Free Pressure-Free Optical Scanning |
Unknown status |
NCT00671385
|
|
|
9 |
Ultra-sounded Guided Regional Blockade for Lipoma Excision |
Completed |
NCT02753361
|
Not Applicable |
|
10 |
Periampullary Lesions Via ERCP in Assuit University Hospital |
Recruiting |
NCT03185390
|
Not Applicable |
|
11 |
Pilot Study of Infrared Imaging of Cutaneous Melanoma |
Completed |
NCT00937690
|
|
|
12 |
Feasibility and Yield of a New 20 G ProCore Needle With Coiled Sheath in the Gastrointestinal Subepithelial Tumors |
Completed |
NCT02884154
|
Not Applicable |
|
13 |
Insight Into Subcutaneous Adipose Tissue Disorders |
Recruiting |
NCT02838277
|
|
|
14 |
Evaluation of Virtual Touch Tissue Imaging Quantification (VTIQ - 2D-SWE) in the Assessment of BI-RADS® 3 and 4 Lesions |
Recruiting |
NCT02638935
|
Not Applicable |
|
15 |
Identification of Biomarkers for Patients With Vascular Anomalies |
Recruiting |
NCT03001180
|
|
|
|